Treatment
Cyclophosphamid clinical trials
We’re tracking 526 recruiting studies that include Cyclophosphamid, each written for real people, not researchers, below.
Recruiting studies
- NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Orange, CaliforniaAges 18–75 - NCT05600686RecruitingPhase 2
New treatment plan for high-risk aggressive lymphoma
This Phase 2 study tests a treatment sequence for people with high-risk diffuse large B-cell lymphoma (DLBCL) that includes loncastuximab plus rituximab, then DA-EPOCH-R. It aims to improve responses in patients whose lymphoma has specific high-risk features.
Sacramento, CaliforniaAges 18 years+ - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Scottsdale, ArizonaAges 18 years+ - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06781944RecruitingPhase 3
Obinutuzumab vs standard treatment for membranous nephropathy
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06647953RecruitingPhase 3
Testing a standard approach for pleuropulmonary blastoma, with or without topotecan
This trial compares a standard surgery and chemotherapy plan for type I pleuropulmonary blastoma (PPB) to adding the drug topotecan for types II and III PPB. The goal is to see if the extra drug helps shrink tumors and improve outcomes for children with more advanced disease.
Birmingham, AlabamaAges Up to 21 years - NCT06563245RecruitingPhase 2/Phase 3
Brentuximab vedotin for Hodgkin lymphoma in children and young adults
This trial tests the drug brentuximab vedotin for children and young adults (ages 2 to under 35) who have just been diagnosed with classical Hodgkin lymphoma. The treatment is guided by PET/CT scans to see how well it works.
ShanghaiAges 2–35 - NCT06041893Recruiting
Stem cell transplant with gentler immune therapy
This trial offers a stem cell transplant from a half-matched (haploidentical) donor for children. It uses an early medicine to calm the immune system and a lower dose of a drug to prevent rejection and graft-versus-host disease.
SeoulAges Any age - NCT05678933Enrolling by invitationPhase 3
Test adding a targeted drug to CHOP for untreated PTCL
This Phase 3 study compares two chemo options—CHOP alone versus CHOP plus AC—for people whose peripheral T-cell lymphoma is the “T-follicular helper” type (PTCL-TFH). The goal is to see which treatment works better for people who have not received lymphoma treatment yet.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT04745949RecruitingPhase 2
Testing first-line antibody plus immunotherapy for mediastinal lymphoma
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
Houston, TexasAges 18 years+ - NCT04432714RecruitingPhase 1/Phase 2
Lenalidomide plus R-DA-EPOCH for MYC-rearranged lymphoma
This early-phase study tests whether lenalidomide combined with R-DA-EPOCH can treat untreated diffuse large B-cell lymphoma (DLBCL) that has a MYC rearrangement. It may help control the lymphoma, but it’s also designed to find the safest and most effective dosing.
Nanjing, JiangsuAges 18–60 - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years - NCT05279300RecruitingPhase 1
Study drug CS5001 for advanced solid tumors and B-cell lymphomas
This Phase 1 study tests how safe and effective CS5001 is for people with advanced (not curable by standard local treatment) solid tumors or B-cell lymphomas. It’s for cancers that have come back or worsened after prior standard treatments.
East Setauket, New YorkAges 18 years+ - NCT04083183RecruitingPhase 1/Phase 2
Testing radiation plus antibody therapy for certain non-cancer diseases
This early-phase study tests a conditioning treatment using total-body irradiation and a radioactive antibody (called astatine-211) before a stem cell transplant for non-cancer conditions. The goal is to improve how well the donor cells take hold and are tolerated.
Seattle, WashingtonAges 18–49 - NCT04237623RecruitingPhase 2
GM-CSF after transplant using a matched related donor
This Phase 2 study tests whether giving a medicine called GM-CSF after an allogeneic transplant (using a matched related donor) can improve outcomes. Participants must meet health and donor-matching requirements and be eligible to safely receive the treatment and consent to the study.
Atlanta, GeorgiaAges 18–78 - NCT04196413RecruitingPhase 1
CAR T cell treatment for a specific brainstem glioma mutation
This Phase 1 study tests a custom immune therapy called GD2 CAR T cells in children and adults with a specific type of diffuse midline glioma (DMG) that has the H3K27M mutation. The goal is to see if the treatment is safe and can help control the cancer.
Stanford, CaliforniaAges 2–60 - NCT02797717Recruiting
Treatment study for classical Hodgkin lymphoma in young people
This trial looks at a treatment approach for children and adolescents with classical Hodgkin lymphoma. It may help by testing how well the treatment controls the cancer and is tolerable in young patients.
Petah TikvaAges 1 month–18 years - NCT02161783Recruiting
Second transplant for blood stem cell graft failure
This trial studies treatment after a first stem cell transplant fails to produce lasting blood recovery. It may help people who need a second transplant because their counts never fully recovered or then dropped again.
Minneapolis, MinnesotaAges Any age - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Atlanta, GeorgiaAges 1–30 - NCT04576143RecruitingPhase 2/Phase 3
Dose-dense chemo before surgery for HER2-negative breast cancer
This trial studies a faster, higher-frequency chemotherapy schedule given before surgery for HER2-negative breast cancer. It aims to see if this approach works better and is safe for the patient’s cancer stage.
Hangzhou, ZhejiangAges 18–70 - NCT06838832RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07074496RecruitingEarly Phase 1
Combined cell therapy for newly diagnosed Ph+ ALL
This trial tests a new combination treatment using ThisCART19A cells and olverembatinib in adults newly diagnosed with a type of leukemia that has the Philadelphia chromosome. It aims to see if this approach is safe and effective.
Suzhou, JiangsuAges 18 years+ - NCT06241456RecruitingPhase 1
Experimental CAR-T cells targeting HER2 for advanced solid tumors
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
Gilbert, ArizonaAges 18 years+
Common questions
- Are there clinical trials studying Cyclophosphamid?
- Yes. Clin2 currently lists 526 recruiting studies that include Cyclophosphamid, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cyclophosphamid trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cyclophosphamid an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cyclophosphamid or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.